The Hashimoto’s thyroiditis market is being driven by growing awareness, better diagnostic screening (especially thyroid autoantibodies), and more refined hormone replacement therapies. Key players like Merck, Abbott, and Novartis are investing in improved treatment protocols. Increased prevalence of autoimmune diseases and rising healthcare access are boosting demand, while ongoing research into immunomodulatory approaches may open new therapeutic avenues. Access Market Report: https://shorturl.at/yOBmo